{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:20:52Z","timestamp":1768915252416,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1007\/s00347-007-1512-2","type":"journal-article","created":{"date-parts":[[2007,3,19]],"date-time":"2007-03-19T14:37:13Z","timestamp":1174315033000},"page":"336-344","source":"Crossref","is-referenced-by-count":37,"title":["Antiangiogene Therapie am vorderen Augenabschnitt","Inhibition of angiogenesis in the anterior chamber of the eye"],"prefix":"10.1007","volume":"104","author":[{"given":"F.","family":"Bock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Baier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cursiefen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1512_CR1","doi-asserted-by":"crossref","unstructured":"Bock F, Onderka J, Dietrich T et al. (2007) Bevacizumab is a potent inhibitor of inflammatory angiogenesis and lymphangiogenesis in the cornea. Invest Ophthalmol Vis Sci (im Druck)","DOI":"10.1167\/iovs.06-0570"},{"key":"1512_CR2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nm1078","volume":"10","author":"Chen","year":"2004","unstructured":"Chen L, Hamrah P, Cursiefen C et al. (2004) Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) mediates dendritic cell migration to lymph nodes and induction of immunity to corneal transplants. Nature Medicine 10: 813\u2013815","journal-title":"Nature Medicine"},{"key":"1512_CR3","doi-asserted-by":"crossref","unstructured":"Cursiefen C (2007) Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy. 92: 50\u201357","DOI":"10.1159\/000099253"},{"key":"1512_CR4","first-page":"2127","volume":"43","author":"Cursiefen","year":"2002","unstructured":"Cursiefen C, Schl\u00f6tzer-Schrehardt U, K\u00fcchle M et al. (2002) Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and Podoplanin. Invest Ophthalmol Vis Sci 43: 2127\u20132135","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1512_CR5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00003226-200304000-00021","volume":"22","author":"Cursiefen","year":"2003","unstructured":"Cursiefen C, Chen L, Dana MR et al. (2003) Corneal lymphangiogenesis: Evidence, mechanisms and implications for transplant immunology. Cornea 22: 273\u20132781","journal-title":"Cornea"},{"key":"1512_CR6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00347-003-0798-y","volume":"100","author":"Cursiefen","year":"2003","unstructured":"Cursiefen C, Seitz B, Dana MR et al. (2003) Angiogenese und Lymphangiogenese in der Hornhaut: Pathogenese, Klinik und Therapieoptionen. Ophthalmologe 100: 292\u2013299","journal-title":"Ophthalmologe"},{"key":"1512_CR7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/01.ico.0000214230.21238.3d","volume":"25","author":"Cursiefen","year":"2006","unstructured":"Cursiefen C, Rummelt C, Neuhuber W et al. (2006) Absence of blood and lymphatic vessels in the developing human cornea. Cornea 25: 722\u2013726","journal-title":"Cornea"},{"key":"1512_CR8","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","volume":"45","author":"Cursiefen","year":"2004","unstructured":"Cursiefen C, Maruyama K, Liu Y et al. (2004) Inhibition of hem- and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45: 2666\u20132673","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1512_CR9","doi-asserted-by":"crossref","first-page":"11405","DOI":"10.1073\/pnas.0506112103","volume":"USA103","author":"Cursiefen","year":"2006","unstructured":"Cursiefen C, Chen L, Saint-Geniez M et al. (2006) Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA103: 11405\u201311410","journal-title":"Proc Natl Acad Sci"},{"key":"1512_CR10","first-page":"A","volume":"102","author":"Cursiefen","year":"2005","unstructured":"Cursiefen C, Seitz B, Kruse F (2005) Hornhauttransplantation: Gl\u00e4nzende Bilanz und viele Perspektiven. Deutsches \u00c4rztebl 102: A-3078","journal-title":"Deutsches \u00c4rztebl"},{"key":"1512_CR11","doi-asserted-by":"crossref","unstructured":"Cursiefen C, Chen L, Borges L, Jackson D, D\u2019Amore PA, Dana MR, Wiegand SJ, Streilein JW. Via bone marrow-derived macrophages, VEGF A mediates lymph- and hemangiogenesis in inflammatory neovascularization. J Clin Investigation 113: 1040\u20131050","DOI":"10.1172\/JCI20465"},{"key":"1512_CR12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0002-9440(10)62355-3","volume":"166","author":"Cursiefen","year":"2005","unstructured":"Cursiefen C, Ikeda S, Nishina PM et al. (2005) Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3-signaling. Am J Pathol 166: 1367\u20131377","journal-title":"Am J Pathol"},{"key":"1512_CR13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1167\/iovs.03-0940","volume":"45","author":"Cursiefen","year":"2004","unstructured":"Cursiefen C, Masli S, Ng TF et al. (2004) Roles of thrombospondin 1 and 2 in regulating spontaneous and induced angiogenesis in the cornea and iris. Invest Ophthalmol Vis Sci 45: 1117\u20131124","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1512_CR14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/01.ico.0000183485.85636.ff","volume":"25","author":"Cursiefen","year":"2006","unstructured":"Cursiefen C, Maruyama M, Jackson DG et al. (2006) Time-course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 25: 443\u2013447","journal-title":"Cornea"},{"key":"1512_CR15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/00003226-200210000-00003","volume":"21","author":"Cursiefen","year":"2002","unstructured":"Cursiefen C, Martus P, Nguyen NX et al. (2002) Corneal neovascularization after nonmechanical versus mechanical corneal trephination for non-high-risk keratoplasty. Cornea 21: 648\u2013652","journal-title":"Cornea"},{"key":"1512_CR16","doi-asserted-by":"crossref","unstructured":"Cursiefen C, Wenkel H, Martus P et al. (2001) Peripheral corneal neovascularization after non-high risk-keratoplasty: influence of short- versus longtime topical steroids. Graefe\u2019s Arch Clin Exp Ophthalmol 239: 514\u2013521.","DOI":"10.1007\/s004170100313"},{"key":"1512_CR17","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1055\/s-2001-16291","volume":"218","author":"Cursiefen","year":"2001","unstructured":"Cursiefen C, Wenkel H, Langenbucher A et al. (2001) Standardisiertes Beurteilungsschema zur semiquantitativen Analyse der kornealen Neovaskularisation mittels projizierter Hornhautphotographien. Klin Monatsbl Augenheilkd 218: 484\u2013491","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1512_CR18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00003226-200007000-00025","volume":"19","author":"Cursiefen","year":"2000","unstructured":"Cursiefen C, Rummelt C, K\u00fcchle M (2000) Immunohistochemical localization of VEGF, TGFa and TGFb1 in human corneas with neovascularization. Cornea 19: 526\u2013533","journal-title":"Cornea"},{"key":"1512_CR19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bjo.87.1.101","volume":"87","author":"Cursiefen","year":"2003","unstructured":"Cursiefen C, Rummelt C, K\u00fcchle M et al. (2003) Pericyte recruitment in human corneal angiogenesis. Br J Ophthalmol 87: 101\u2013106","journal-title":"Br J Ophthalmol"},{"key":"1512_CR20","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1055\/s-2006-926875","volume":"223","author":"Geitzenauer","year":"2006","unstructured":"Geitzenauer W, Michels S, Prager F et al. (2006) Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd 223: 822\u2013827","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1512_CR21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ajo.2006.02.045","volume":"142","author":"Grisanti","year":"2006","unstructured":"Grisanti S, Biester S, Peters S et al. (2006) Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 142: 158\u2013160","journal-title":"Am J Ophthalmol"},{"key":"1512_CR22","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ajo.2006.06.066","volume":"142","author":"Iliev","year":"2006","unstructured":"Iliev ME, Domig D, Wolf-Schnurrbursch U (2006) Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142: 1054\u20131056","journal-title":"Am J Ophthalmol"},{"key":"1512_CR23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000099248","volume":"39","author":"Jonas","year":"2007","unstructured":"Jonas JB, Spandau UH, Schlichtenbrede F (2007) Intravitreal Bevacizumab for filtering surgery. Ophthalmic Res 39: 121\u2013122","journal-title":"Ophthalmic Res"},{"key":"1512_CR24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3928\/1542-8877-20060301-12","volume":"37","author":"Kahook","year":"2006","unstructured":"Kahook MY, Schumann JS, Noecker RJ (2006) Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging 37: 148\u2013150","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"1512_CR25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00347-006-1404-x","volume":"103","author":"Klink","year":"2006","unstructured":"Klink T, Guthoff R, Grehn F (2006) Postoperative care after glaucoma filtration surgery. Ophthalmologe 103: 815\u2013823","journal-title":"Ophthalmologe"},{"key":"1512_CR26","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1076\/ceyr.17.10.986.5245","volume":"17","author":"Kria","year":"1998","unstructured":"Kria L, Ohira A, Amemiya T (1998) TNP-470 (a fungus-derived inhibitor of angiogenesis) reduces proliferation of cultured fibroblasts isolated from primary pterygia: a possible drug therapy for pterygia. Curr Eye Res 17: 986\u2013993","journal-title":"Curr Eye Res"},{"key":"1512_CR27","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.ico.0000157400.81408.2b","volume":"24","author":"Kuhlmann","year":"2005","unstructured":"Kuhlmann A, Amann K, Schl\u00f6tzer-Schrehardt U (2005) Endothelin-1 and Eta\/Etb-receptor expression in normal & vascularized human cornea. Cornea 24: 837\u2013844","journal-title":"Cornea"},{"key":"1512_CR28","doi-asserted-by":"crossref","unstructured":"Manzano R et al. (2007) Inhibition of experimental corneal neovascularization by Bevacizumab (AVASTIN). Br J Ophthalmol (in press)","DOI":"10.1136\/bjo.2006.107912"},{"key":"1512_CR29","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1172\/JCI23874","volume":"115","author":"Maruyama","year":"2005","unstructured":"Maruyama K, Li M, Cursiefen C et al. (2005) Inflammatory lymphangiogenesis arises from CD11b+ cells. J Clin Invest 115: 2363\u20132372","journal-title":"J Clin Invest"},{"key":"1512_CR30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1055\/s-2004-813282","volume":"221","author":"Nguyen","year":"2004","unstructured":"Nguyen N, Seitz B, Langenbucher A et al. (2004) Clinical aspects and treatment of immune reactions following penetrating normal-risk keratoplasty. Klin Monatsbl Augenheilkd 221: 467\u2013472","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1512_CR31","first-page":"2148","volume":"41","author":"Pillai","year":"2000","unstructured":"Pillai CT, Dua HS, Hossain P (2000) Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 41: 2148\u20132153","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1512_CR32","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nbt995","volume":"22","author":"Shaunak","year":"2004","unstructured":"Shaunak S, Thomas S, Gianasi E et al. (2004) Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 22: 977\u2013984","journal-title":"Nat Biotechnol"},{"key":"1512_CR33","doi-asserted-by":"crossref","unstructured":"Shojaei F, Ferrara N (2007) Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest (Epub ahead of print)","DOI":"10.1038\/labinvest.3700526"},{"key":"1512_CR34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ajo.2005.08.080","volume":"141","author":"Vinh","year":"2006","unstructured":"Vinh L, Nguyen N, Martus P (2006) Surgery-related factors influencing corneal neovascularization after low-risk keratoplasty. Am J Ophthalmol 141: 260\u2013266","journal-title":"Am J Ophthalmol"},{"key":"1512_CR35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1006\/exer.1994.1037","volume":"58","author":"Wong","year":"1994","unstructured":"Wong J, Wang N, Miller JW (1994) Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res 58: 439\u2013451","journal-title":"Exp Eye Res"},{"key":"1512_CR36","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1517\/14656566.7.17.2355","volume":"7","author":"Yeoh","year":"2006","unstructured":"Yeoh J, Sims J, Guymer RH (2006) A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother 7: 2355\u20132368","journal-title":"Expert Opin Pharmacother"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-007-1512-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-007-1512-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-007-1512-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:50:47Z","timestamp":1559051447000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-007-1512-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["1512"],"URL":"https:\/\/doi.org\/10.1007\/s00347-007-1512-2","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}